RAAV-based compositions and methods
The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).
1. A method of simultaneously expressing an exogenous protein and decreasing expression of an endogenous protein in a subject, comprising: administering an effective amount of an isolated nucleic acid to a subject, wherein the isolated nucleic acid comprises:
(a) a first region that encodes one or more first miRNAs comprising a nucleic acid having sufficient sequence complementary with an endogenous mRNA of a subject to hybridize with and inhibit expression of the endogenous mRNA, wherein the endogenous mRNA encodes a first protein; and
(b) a second region encoding an exogenous mRNA that encodes a second protein, wherein the second protein has an amino acid sequence that is at least 85% identical to the first protein,
wherein the one or more first miRNAs do not comprise a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the exogenous mRNA, and wherein the first region is positioned within an untranslated portion of the second region.
2. The isolated nucleic acid of claim 1 , further comprising a third region encoding a one or more second miRNAs comprising a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the endogenous mRNA, wherein the third region is positioned within an untranslated portion of the second region.
3. The method of claim 1 , wherein the untranslated portion is an intron.
4. The method of claim 1 , wherein the first region encodes two or more first miRNA.
5. The method of claim 2 , wherein the third region encodes two or more second miRNA.
6. The method of claim 1 , wherein the isolated nucleic acid further comprises a promoter operably linked with the region(s) encoding the one or more first miRNAs, the exogenous mRNA, and/or the one or more second miRNAs.
7. The method of claim 6 , wherein the promoter is a tissue-specific promoter.
8. The method of claim 6 , wherein the promoter is a beta-actin promoter (β-actin).
9. The method of claim 1 , wherein the isolated nucleic acid is administered to muscle tissue, liver tissue, or lung tissue of the subject.
10. The method of claim 1 , wherein the administration is by intravenous administration, intramuscular administration, subcutaneous administration, or intraperitoneal administration.
11. A method of simultaneously expressing an exogenous protein and decreasing expression of an endogenous protein in a subject, comprising: administering an effective amount of an isolated nucleic acid to a subject, wherein the isolated nucleic acid comprises:
(a) a first region encoding one or more first miRNAs comprising a nucleic acid having sufficient sequence complementary with an endogenous mRNA of a subject to hybridize with and inhibit expression of the endogenous mRNA, wherein the endogenous mRNA encodes a first protein; and
(b) a second region encoding an exogenous mRNA that encodes a second protein, wherein the second protein has an amino acid sequence that is at least 85% identical to the first protein,
wherein the one or more first miRNAs do not comprise a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the exogenous mRNA, and wherein the first region is positioned downstream of a portion of the second region encoding the poly-A tail of the exogenous mRNA.
12. The method of claim 11 , further comprising a third region encoding a one or more second miRNAs comprising a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the endogenous mRNA, wherein the third region is positioned within an untranslated portion of the second region.
13. The method of claim 11 , wherein the untranslated portion is an intron.
14. The method of claim 11 , wherein the first region encodes two or more first miRNA.
15. The method of claim 12 , wherein the third region encodes two or more second miRNA.
16. The method of claim 11 , wherein the isolated nucleic acid further comprises a promoter operably linked with the region(s) encoding the one or more first miRNAs, the exogenous mRNA, and/or the one or more second miRNAs.
17. The method of claim 16 , wherein the promoter is a tissue-specific promoter.
18. The method of claim 16 , wherein the promoter is a beta-actin promoter (β-actin).
19. The method of claim 11 , wherein the isolated nucleic acid is administered to muscle tissue, liver tissue, or lung tissue of the subject.
20. The method of claim 11 , wherein the administration is by intravenous administration, intramuscular administration, subcutaneous administration, or intraperitoneal administration.